Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-06-28
1996-07-02
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 12, 530350, 530303, 530397, A61K 3800, C07K 1700
Patent
active
055322166
ABSTRACT:
Bactericidal/permeability-increasing protein (BPI) is useful to neutralize non-lipopolysaccharide compounds capable of stimulating TNF production and has application in vitro and in vivo for therapeutics and prophylactic treatment. This use of BPI can be combined with the administration of materials, such as an enzyme, microorganism, living cells or cell fractions, encapsulated in alginate gels.
REFERENCES:
patent: 4950600 (1990-08-01), Tanaka et al.
patent: 5089274 (1992-02-01), Marra et al.
patent: 5348942 (1994-09-01), Little, II et al.
Otterelei et al, Journal of Immunotherapy, vol. 10, No. 4, pp. 286-291, 1991.
Otterelei et al, Infection and Immunity, vol. 61, No. 5, pp. 1917-1925, May 1993.
Lim, Science, vol. 210, pp. 908-910, 21 Nov., 1980.
Dentener et al., "Antagonistic Effects of Lipopolysaccharide Binding Protein and Bactericidal/Permeability-Increasing Protein on Lipopolysaccharide-Induced Cytokine Release by Mononuclear Phagocytes: Competition for Binding to Lipopolysaccharide," J. Immuno. (1993) 151(8):4258-65.
Heumann et al., "Competition between Bactericidal/Permeability-Increasing Protein and Lipopolysaccharide-Binding Protein for Lipopolysaccaride Binding to Monocytes," J. Infect. Diseases (1993) 167:1351-57.
Capodici et al., "Effect of Lipopolysaccharide (LPS) Chain Length on Interactions of Bactericidal/Permeabilty-Increasing Protein and its Bioactive 23-Kilodalton NH.sub.2 -Terminal Fragment with Isolated LPS and Intact Proteus mirabilis and Escherichia coli," Infect. Immun. (1994) 62(1):259-65.
Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin," J. Immunol. (1992) 148(2):532-7.
Weiss et al., "Human Bactericidal/Permeability-Increasing Protein and a Recombinant NH.sub.2 -Terminal Fragment Cause Killing of Serum-resistant Gram-negative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria," J. Clin. Invest. (1992)90:1122-30.
Otterlei et al., "Similar Mechanisms of Action of Defined Polysaccharides and Lipopolysaccharides: Characterization of Binding and Tumor Necrosis Factor Alpha Induction," Infect. Immun. (1993) 61(5):1917-25.
Marra et al., "Bactericidal/Permeability-Increasing Protein has Endotoxin-Neutralizing Activity," J. Immuno. (1980) 144(2):662-666.
Lim et al., "Microencapsulated Islets as Bioartificial Endocrine Pancreas," Science (1980) 210:908-910.
O'Shea et al., "Prolonged Survival of Transplated Islets of Langerhans Encapsulated in a Biocompatible Membrane," Biochem. Biophys. ACTA (1984) 804:133-136.
Sun et al., "Microencapsulated Cells as Hormone Delivery Systems," CRC Critical Rev. Thera. Drug Carrier Systems (1987) 4:1-12.
Sun et al., "Encapsulated Versus Modified Endocrine Cells for Organ Replacement," Trans Am Soc Artif Intern Organs (1987) 33:787-790.
Tze et al., "Biocompatibility and Immunological Studies of Microencapsulation with Cross-Linked Alginate Capsules," Transplanation (1982) 33(5):563-564.
Miura et al., "Synthesis and Secretion of Protein by Hepatocytes Entrapped within Calcium Alginate," Artificial Organs (1986) 10(6):460-465.
Darquy et al., "Microencapsulation of Parathyroid Cells as a Bioartificial Parathyroid," Trans Am Soc Artif Intern Organs (1987) 33:356-358.
Otterlei et al., "Induction of Cytokine Production from Human Monocytes Stimulated with Alginate," J. Immuno. (1991) 10:286-291.
Sun et al., Topics in Pharmaceutical Science, Elsevier Science Publishers, Amsterdam, (1985) p. 93.
Goosen et al., Biotechnol. Bioeng. (1985) 27:146.
Soon-Shiong et al., "Successful Reversal of Spontaneous Diabetes in Dogs by Intraperitoneal Microencapsulated Islets," Transplantation (1992) 54:769-774.
Tompkins et al., Biotechnol. Bioeng. (1988) 31:11.
Espevik Terje
Marra Marian N.
Bozicevic Karl
Chan Christina Y.
Francis Carol L.
Incyte Pharmaceuticals Inc.
Mohamed Abdel A.
LandOfFree
Neutralization of non-lipopolysaccharide compounds by bactericid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralization of non-lipopolysaccharide compounds by bactericid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralization of non-lipopolysaccharide compounds by bactericid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1506419